What is Exonate?
Exonate is a biopharmaceutical company dedicated to developing innovative treatments for retinal vascular diseases, particularly focusing on Age Related Macular Degeneration and diabetic eye diseases. Their lead product, EXN407, aims to be the first topical therapy for conditions like diabetic retinopathy and is expected to enter Phase IIb clinical trials in 2026. The company specializes in small molecule drugs that modulate alternative mRNA splicing to combat diseases characterized by pathological blood vessel formation. Exonate's mission is to transform the lives of patients suffering from vision loss by addressing high unmet medical needs.
How much funding has Exonate raised?
Exonate has raised a total of $6.8M across 2 funding rounds:
Angel/Seed
$660K
Grant
$6.1M
Angel/Seed (2015): $660K with participation from University of Nottingham and Fusion IP PLC
Grant (2017): $6.1M led by Wellcome Trust
Key Investors in Exonate
Wellcome Trust
Wellcome is an independent global charitable foundation based in London that supports discovery research and tackles urgent health challenges, funding science, policy and public engagement to improve health for people everywhere through grants, partnerships and advocacy.
Fusion IP PLC
IP Group is a conglomerate that specializes in intellectual property commercialization, transforming innovative ideas from university partnerships into viable businesses. Founded in 2001 and publicly traded on the London Stock Exchange, the company provides comprehensive support including business expertise, capital investment, networking opportunities, and operational assistance.
University of Nottingham
Founded in 1881, University of Nottingham is a public research university in Nottingham, United Kingdom. Departments include Humanities, Engineering, Medicine, Sciences and Social Sciences.
What's next for Exonate?
With the recent infusion of major strategic capital, Exonate is poised to advance its pipeline, particularly EXN407, towards its upcoming Phase IIb clinical trials in 2026. This significant investment will likely accelerate research and development efforts, potentially enabling the company to solidify its position as a leader in addressing high unmet medical needs within the ophthalmology sector. The company's focus on modulating alternative mRNA splicing represents a novel therapeutic approach, suggesting a strong emphasis on innovation and scientific advancement as it moves towards commercialization.
See full Exonate company page
